Literature DB >> 16236557

The use of unequal randomisation ratios in clinical trials: a review.

J C Dumville1, S Hahn, J N V Miles, D J Torgerson.   

Abstract

OBJECTIVE: To examine reasons given for the use of unequal randomisation in randomised controlled trials (RCTs). MAIN MEASURES: Setting of the trial; intervention being tested; randomisation ratio; sample size calculation; reason given for randomisation.
METHODS: Review of trials using unequal randomisation. DATABASES AND SOURCES: Cochrane library, Medline, Pub Med and Science Citation Index.
RESULTS: A total of 65 trials were identified; 56 were two-armed trials and nine trials had more than two arms. Of the two-arm trials, 50 trials recruited patients in favour of the experimental group. Various reasons for the use of unequal randomisation were given. Six studies stated that they used unequal randomisation to reduce the cost of the trial, with one screening trial limited by the availability of the intervention. Other reasons for using unequal allocation were: avoiding loss of power from drop-out or cross-over, ethics and the gaining of additional information on the treatment. Thirty seven trials papers (57%) did not state why they had used unequal randomisation and only 14 trials (22%) appeared to have taken the unequal randomisation into account in their sample size calculation.
CONCLUSION: Although unequal randomisation offers a number of advantages to trials the method is rarely used and is especially under-utilised to reduce trial costs. Unequal randomisation should be considered more in trial design especially where there are large differences between treatment costs.

Entities:  

Mesh:

Year:  2005        PMID: 16236557     DOI: 10.1016/j.cct.2005.08.003

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  84 in total

1.  Reducing Risk Behavior with Family-Centered Prevention During the Young Adult Years.

Authors:  Elizabeth Stormshak; Allison Caruthers; Krista Chronister; David DeGarmo; Jenna Stapleton; Corrina Falkenstein; Elisa DeVargas; Whitney Nash
Journal:  Prev Sci       Date:  2019-04

2.  Are outcome-adaptive allocation trials ethical?

Authors:  Spencer Phillips Hey; Jonathan Kimmelman
Journal:  Clin Trials       Date:  2015-02-03       Impact factor: 2.486

3.  Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.

Authors:  Sandra A Springer; Angela Di Paola; Russell Barbour; Marwan M Azar; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

4.  Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group.

Authors:  Yevgen Ryeznik; Oleksandr Sverdlov; Andrew C Hooker
Journal:  AAPS J       Date:  2018-07-19       Impact factor: 4.009

5.  Multiple Family Groups to reduce child disruptive behavior difficulties: moderating effects of child welfare status on child outcomes.

Authors:  Geetha Gopalan; Latoya Small; Ashley Fuss; Melissa Bowman; Jerrold Jackson; Sue Marcus; Anil Chacko
Journal:  Child Abuse Negl       Date:  2015-07-16

6.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

7.  A Randomized Controlled Trial of Healthy Families: 6-Month and 1-Year Follow-Up.

Authors:  Craig Winston LeCroy; Darlene Lopez
Journal:  Prev Sci       Date:  2020-01

8.  Pharmaceutical care of adolescents with diabetes mellitus type 1: the DIADEMA study, a randomized controlled trial.

Authors:  Emina Obarcanin; Manfred Krüger; Petra Müller; Verena Nemitz; Holger Schwender; Snijezana Hasanbegovic; Sena Kalajdzisalihovic; Stephanie Läer
Journal:  Int J Clin Pharm       Date:  2015-04-28

9.  Optimum treatment allocation rules under a variance heterogeneity model.

Authors:  Weng Kee Wong; Wei Zhu
Journal:  Stat Med       Date:  2008-09-30       Impact factor: 2.373

10.  Distress intolerance during smoking cessation treatment.

Authors:  Samantha G Farris; Teresa M Leyro; Nicholas P Allan; Camilla S Øverup; Norman B Schmidt; Michael J Zvolensky
Journal:  Behav Res Ther       Date:  2016-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.